Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

442
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
442
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

2.0K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient Selection for Protected Percutaneous Coronary Intervention: Who Benefits the Most?

Interventional cardiology clinics·2022
Same author

Early echocardiographic evaluation of right ventricular load adaptability after sequential combination treatment in pulmonary arterial hypertension.

Herz·2022
Same author

Radiofrequency ablation of atrial fibrillation-50 W or 90 W?

Journal of cardiovascular electrophysiology·2022
Same author

Should HFrEF patients with NYHA class II expect benefit from CCM therapy? Results from the MAINTAINED observational study.

Clinical research in cardiology : official journal of the German Cardiac Society·2022
Same author

Carvedilol versus Metoprolol in Patients with Ventricular Tachyarrhythmias.

Journal of cardiovascular development and disease·2022
Same author

A Preclinical Study on Brugada Syndrome with a CACNB2 Variant Using Human Cardiomyocytes from Induced Pluripotent Stem Cells.

International journal of molecular sciences·2022

Related Experiment Video

Updated: Apr 25, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

27.4K

Recent developments in drug-eluting coronary stents.

Mustafa Yildiz, Banu Sahin Yildiz, Mustafa Ozan Gursoy

  • 1Medical Faculty Mannheim, University Heidelberg, Theodor-Kutzer Ufer 1-3, 68167 Mannheim, Germany. Ibrahim.akin@umm.de.

Cardiovascular & Hematological Disorders Drug Targets
|September 2, 2014
PubMed
Summary

Drug-eluting stents (DES) have evolved significantly since their introduction, improving outcomes for coronary artery disease. Newer generations show promise, but large-scale comparisons are still needed.

More Related Videos

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

8.6K
Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

9.3K

Related Experiment Videos

Last Updated: Apr 25, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

27.4K
Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

8.6K
Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

9.3K

Area of Science:

  • Interventional Cardiology
  • Biomaterials Science

Background:

  • Coronary artery disease (CAD) treatment has advanced from balloon angioplasty to stenting.
  • Early drug-eluting stents (DES) reduced restenosis but faced issues with late stent thrombosis.
  • Bare-metal stents (BMS) have higher restenosis rates compared to DES.

Purpose of the Study:

  • To review the evolution of coronary stenting, focusing on drug-eluting stents (DES).
  • To highlight advancements in DES technology, including newer generations.
  • To identify the current data limitations regarding third-generation DES efficacy.

Main Methods:

  • Literature review of interventional cardiology treatments for CAD.
  • Analysis of clinical trial and registry data on stent performance.
  • Examination of stent design evolution, including polymers and platforms.

Main Results:

  • Plain old balloon angioplasty (POBA) had high restenosis rates (20-40%).
  • First-generation DES reduced restenosis to 6-8% but had thrombosis concerns.
  • Second-generation DES demonstrated improved clinical and angiographic results over BMS.

Conclusions:

  • Coronary stent technology has progressed substantially, with significant improvements in DES.
  • Third-generation DES, utilizing biodegradable materials, are under investigation.
  • Large-scale comparative data for third-generation DES against earlier generations is currently lacking.